---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-032197"
form_type: "8-K"
ticker: "CELC"
cik: "0001603454"
company_name: "Celcuity Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:20:13.793060+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Celcuity Q2 net loss widens to $23.7M; VIKTORIA-1 PIK3CA WT cohort enrollment delayed to Q4 2024

## Summary
- Net loss of $23.7M ($0.62/share) vs $14.6M ($0.66/share) YoY; non-GAAP adjusted loss per share $0.58.
- R&D expenses rose to $22.5M, driven by VIKTORIA-1 Phase 3 and initiation of Phase 1b/2 mCRPC trial.
- Raised $129M gross from equity and debt financings, extending cash runway through 2026.
- VIKTORIA-1 PIK3CA WT cohort enrollment target shifted to Q4 2024; topline data expected late Q4 2024 to Q1 2025.
- Plan to initiate Phase 3 VIKTORIA-2 trial in first-line HR+/HER2- advanced breast cancer; first patient expected Q2 2025.

## SEC filing metadata
- accession: 0001493152-24-032197
- form_type: 8-K
- ticker: CELC
- cik: 0001603454
- company_name: Celcuity Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1603454/000149315224032197/0001493152-24-032197-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1603454/000149315224032197/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-032197
- JSON: https://secwatch.observer/filing/0001493152-24-032197.json
- Plain text: https://secwatch.observer/filing/0001493152-24-032197.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.